1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

19 Mar 2024
Admin
News Article

Arch Biopartners & Univ of Calgary Join Hands for LSALT Peptide Trial

Arch Biopartners announces Univ of Calgary joins with phase II trial of LSALT peptide to treat cardiac surgery-associated acute kidney injury

Overview

Arch Biopartners Inc, a late-stage clinical trial company focused on preventing inflammation and acute organ injury, has announced that a research team from the University of Calgary’s Cumming School of Medicine has joined the phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.

Words from Principal Investigator

“We know that acute kidney injury impairs recovery and can negatively affect long-term outcomes following heart surgery. Our research team is excited to participate in a study working towards improving kidney health in our patients.” said Alex Gregory MD, Assistant Professor and Director of Research, Division of Cardiovascular Anesthesia at the Libin Cardiovascular Institute at the Cumming School of Medicine, and site principal investigator for the LSALT Phase II CS-AKI trial.

Dr. Gregory’s clinical team has submitted an application to the local Research Ethics Board for permission to participate in the trial.

Clinical Sites

The addition of the first Canadian clinical site increases the number of trial sites to four, with three hospitals in Turkey currently recruiting patients.
There are three additional hospital sites in Turkey pending activation into the trial.
The Arch Biopartners team is currently working with two other hospital sites in Canada to prepare for their participation in this phase II trial.

CS-AKI Phase II Trial

The CS-AKI phase II trial is an international multi-center, randomized, double-blind, placebo-controlled study of LSALT peptide.
The recruitment target for the trial is 240 patients. The primary objective of the trial is to evaluate the percentage of subjects with AKI within seven days following on-pump (heart-lung machine) cardiac surgery, defined by the KDIGO (Kidney Disease: Improving Global Outcomes) criteria.

About CS-AKI

CS-AKI is often caused by ischemia-reperfusion injury (IRI) that reduces blood flow (ischemia) and thus oxygen in the kidney, causing kidney cell damage.
Once blood flow is restored to normal (reperfusion), inflammation is triggered and injury to kidney cells is exacerbated.
In the worst cases of AKI, kidneys fail, leading to kidney dialysis or kidney transplant. There is no treatment available in the market today that prevents acute kidney injury of the type commonly experienced by on-pump cardiac surgery patients.

Acute Kidney Injury

Acute kidney injury is a known common complication in patients after coronary artery bypass grafting (CABG) and other cardiac surgeries, including on-pump surgeries which increase the risk of acute kidney injury. The reported prevalence of CS-AKI is up to 30% and is independently associated with an increase in morbidity and mortality.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!